LIVZON PHARMAC. GRP H YC1 (LP6) - Net Assets
Based on the latest financial reports, LIVZON PHARMAC. GRP H YC1 (LP6) has net assets worth €15.58 Billion EUR (≈ $18.22 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€24.19 Billion ≈ $28.29 Billion USD) and total liabilities (€8.61 Billion ≈ $10.07 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore LP6 cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €15.58 Billion |
| % of Total Assets | 64.41% |
| Annual Growth Rate | 2.09% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.33 |
LIVZON PHARMAC. GRP H YC1 - Net Assets Trend (2021–2025)
This chart illustrates how LIVZON PHARMAC. GRP H YC1's net assets have evolved over time, based on quarterly financial data. Also explore LIVZON PHARMAC. GRP H YC1 asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below shows the annual net assets of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. For live valuation and market cap data, see LP6 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €15.55 Billion ≈ $18.18 Billion |
+4.30% |
| 2024-12-31 | €14.91 Billion ≈ $17.43 Billion |
+0.94% |
| 2023-12-31 | €14.77 Billion ≈ $17.26 Billion |
-1.14% |
| 2022-12-31 | €14.94 Billion ≈ $17.46 Billion |
+4.37% |
| 2021-12-31 | €14.31 Billion ≈ $16.73 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LIVZON PHARMAC. GRP H YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 31.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €12.74 Billion | 91.72% |
| Other Components | €1.15 Billion | 8.28% |
| Total Equity | €13.89 Billion | 100.00% |
LIVZON PHARMAC. GRP H YC1 Competitors by Market Cap
The table below lists competitors of LIVZON PHARMAC. GRP H YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vivenio Residencial SOCIMI S.A.
MC:YVIV
|
$995.58 Million |
|
Daktronics Inc
NASDAQ:DAKT
|
$995.92 Million |
|
Yuanta Futures Co Ltd
TWO:6023
|
$996.00 Million |
|
Wereldhave NV
AS:WHA
|
$996.10 Million |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
$994.99 Million |
|
Univest Corporation Pennsylvania
NASDAQ:UVSP
|
$994.94 Million |
|
BALTIC CLASSIF.GR LS 001
F:983
|
$994.50 Million |
|
Reysas Tasimacilik ve Lojistik Ticaret AS
IS:RYSAS
|
$994.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LIVZON PHARMAC. GRP H YC1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,862,334,189 to 13,888,350,565, a change of 26,016,376 (0.2%).
- Net income of 2,023,249,328 contributed positively to equity growth.
- Dividend payments of 1,032,995,125 reduced retained earnings.
- Other factors decreased equity by 964,237,827.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.02 Billion | +14.57% |
| Dividends Paid | €1.03 Billion | -7.44% |
| Other Changes | €-964.24 Million | -6.94% |
| Total Change | €- | 0.19% |
Book Value vs Market Value Analysis
This analysis compares LIVZON PHARMAC. GRP H YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.18x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €13.87 | €2.84 | x |
| 2022-12-31 | €14.83 | €2.84 | x |
| 2023-12-31 | €15.20 | €2.84 | x |
| 2024-12-31 | €15.21 | €2.84 | x |
| 2025-12-31 | €15.64 | €2.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LIVZON PHARMAC. GRP H YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.57%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.83%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.73x
- Recent ROE (14.57%) is above the historical average (14.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 13.66% | 14.72% | 0.54x | 1.72x | €475.31 Million |
| 2022 | 13.76% | 15.12% | 0.51x | 1.79x | €521.80 Million |
| 2023 | 13.91% | 15.72% | 0.50x | 1.78x | €549.40 Million |
| 2024 | 14.87% | 17.45% | 0.48x | 1.76x | €674.86 Million |
| 2025 | 14.57% | 16.83% | 0.50x | 1.73x | €634.41 Million |
Industry Comparison
This section compares LIVZON PHARMAC. GRP H YC1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,058,012,174
- Average return on equity (ROE) among peers: -98.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LIVZON PHARMAC. GRP H YC1 (LP6) | €15.58 Billion | 13.66% | 0.55x | $995.44 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.19 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $29.16 Million | -49.27% | 0.13x | $13.93 Million |
| EQL PHARMA AB (7JK) | $221.03 Million | 19.51% | 2.66x | $80.44 Million |
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more